GLIOBLASTOMA

This early-stage study tests a personalized vaccine made from each patient's unique tumor mutations, combined with radiation and an immunotherapy drug (pembrolizumab), for people with newly diagnosed glioblastoma. The goal is to see if the vaccine is safe and can train the immune…

This early study tested a personalized DNA vaccine in 9 people with a newly diagnosed, aggressive type of brain cancer called glioblastoma. The vaccine was custom-made for each person based on their tumor's unique genetic makeup. The main goals were to see if the vaccine was safe…

This study tests a vaccine called SurVaxM, given with standard chemotherapy, for people with a newly diagnosed aggressive brain cancer (glioblastoma). The vaccine is designed to train the immune system to attack cancer cells. The main goal is to see if adding the vaccine helps ke…

This study tests a precise radiation therapy that targets brain tumors while sparing the scalp to reduce wound infections and other side effects. About 100 adults with newly diagnosed grade II to IV gliomas will receive this treatment. The goal is to see if this approach is safer…

This study tests whether giving a dose of radiation directly to the tumor cavity during surgery, on top of the usual radiation and chemotherapy, can help people with a newly diagnosed aggressive brain cancer called glioblastoma live longer without the cancer growing. About 314 ad…

This study tests whether giving a higher, more focused dose of radiation (using advanced photon or proton beams) along with the chemotherapy drug temozolomide helps people with newly diagnosed glioblastoma live longer compared to standard radiation. About 600 participants are enr…

This study tests a combination of a drug called niraparib and a device that delivers low-intensity electric fields (Tumor-Treating Fields) in 30 adults whose glioblastoma brain tumor has come back after radiation. The goal is to see if this treatment can shrink or stabilize the t…

This early-phase study tests a combination of two immunotherapy drugs (domvanalimab and zimberelimab) in people whose glioblastoma has come back after initial treatment. The goal is to check if the drugs are safe for brain tumor patients and to study how they affect the tumor and…

This study tests whether adding the immunotherapy drug pembrolizumab to standard treatment (chemotherapy plus a device that sends electric fields to the brain) can help people with newly diagnosed glioblastoma, an aggressive brain cancer. About 40 adults with good physical functi…

This study tests whether adding anlotinib hydrochloride to the standard Stupp regimen can help people with newly diagnosed glioblastoma live longer without their cancer growing. About 150 adults aged 18-75 with confirmed glioblastoma will receive either the standard treatment plu…

This early-phase study tests a modified virus designed to attack brain tumor cells that have come back or grown despite previous treatment. About 62 adults with certain types of brain cancer will receive the virus directly into the tumor, sometimes with a drug to boost the immune…

This early-phase study tests whether specially engineered immune cells (CAR T cells) can safely target and destroy brain tumor cells that have spread to the lining of the brain and spinal cord. Ten adults with glioblastoma, ependymoma, or medulloblastoma will receive these cells.…

This study tests a combination of an experimental drug (paxalisib), a diabetes drug (metformin), and a high-fat, low-carbohydrate (ketogenic) diet in people with a type of brain cancer called glioblastoma. The goal is to see if this approach is safe and can slow tumor growth. The…

This study tests whether adding the drug azeliragon to standard radiation and chemotherapy is safe for people with newly diagnosed glioblastoma, an aggressive brain cancer. About 18 participants will receive the combination to find the best dose and look for early signs that the …

This study tests the drug tofacitinib in 17 adults with recurrent glioblastoma, a fast-growing brain cancer. The goal is to see if it can slow tumor growth and improve survival. Participants take the drug twice daily, and researchers track how long the cancer stays under control.

This early-phase trial tests whether adding the drug ibrutinib to standard radiation and chemotherapy is safe for people with a newly diagnosed aggressive brain cancer called glioblastoma. The study includes 36 participants and looks at different doses based on a specific genetic…

This study tests a new treatment for people with recurrent glioblastoma, an aggressive brain cancer. Doctors inject immune-boosting cells and two immunotherapy drugs directly into the tumor during surgery, followed by more immunotherapy through a brain reservoir and vein. The goa…

This study tests whether a shorter, higher-dose radiation treatment works as well as the standard longer course for people with glioblastoma, an aggressive brain cancer. About 170 adults with confirmed glioblastoma will receive either short or standard radiation. The goal is to s…

This study tests the drug olaparib in people with advanced solid tumors (including brain tumors and bile duct cancer) that have IDH1 or IDH2 mutations. The goal is to see if olaparib can shrink or slow the growth of these cancers. About 89 participants will receive the drug, and …

This study tests the drug nivolumab in 62 adults with a type of brain tumor (glioma) that has specific gene changes (IDH mutations). The goal is to see if nivolumab can stop or slow tumor growth. Participants receive the drug through an IV every few weeks and are monitored with s…

This study tests whether adding the drug veliparib to standard chemotherapy (temozolomide) helps people with a newly diagnosed, aggressive brain cancer called glioblastoma live longer. The trial includes 447 adults whose tumors have a specific genetic marker (MGMT hypermethylatio…

This study tests whether two targeted drugs, dabrafenib and trametinib, given after radiation therapy can help children and young adults (up to age 25) with a specific type of aggressive brain cancer called BRAF V600-mutant high-grade glioma. The drugs block signals that help can…

This early-stage trial tests an oral drug called gallium maltolate in 26 people whose glioblastoma has returned after standard treatment. The main goal is to find a safe dose and see if it can slow tumor growth. Participants take the drug by mouth and have regular scans to track …

This study tests a drug called niraparib in people with two types of brain tumors: newly diagnosed glioblastoma and recurrent IDH-mutant glioma with ATRX loss. The goal is to see if the drug reaches the tumor and slows its growth. Up to 42 participants will receive niraparib befo…

This early-phase study tests whether adding a personalized vaccine (made from a patient's own tumor mutations) to standard care plus Tumor Treating Fields (electric fields that disrupt cancer growth) is safe and tolerable for people with newly diagnosed glioblastoma, an aggressiv…

This study tests a combination of two drugs, L19TNF and lomustine, in people whose glioblastoma (a fast-growing brain tumor) has come back or gotten worse. The goal is to find the best dose that is safe and may help people live longer. About 90 adults will take part, and research…

This study tests whether starting chemotherapy earlier and continuing it longer can help adults with glioblastoma, an aggressive brain cancer, live longer. About 486 participants were randomly assigned to either the standard treatment or an intensified plan. The goal is to see if…

This early-phase study tests whether specially engineered immune cells (CART-EGFR-IL13Ra2) are safe and feasible for people with a recurrent, aggressive brain cancer called glioblastoma. About 67 adults whose tumors have returned after standard treatment will receive their own mo…

This study tests a new treatment called IGV-001 for people recently diagnosed with glioblastoma, an aggressive brain cancer. The treatment uses a patient's own cells to create a personalized immunotherapy aimed at slowing tumor growth. About 93 participants will receive either IG…

This early-phase trial tests whether giving two immunotherapy drugs (nivolumab and ipilimumab) before surgery can boost the immune system's attack on glioblastoma, an aggressive brain cancer. About 63 patients with recurrent glioblastoma will receive the drugs or a placebo before…

This study tests whether adding the drug veliparib to standard radiation and chemotherapy can help children and young adults with a fast-growing brain tumor called high-grade glioma. Veliparib blocks a protein that helps cancer cells repair themselves, potentially making treatmen…

This study tests whether adding the drug indoximod to standard chemotherapy and radiation can help children aged 3 to 21 with certain brain cancers. The drug aims to boost the body's immune system to fight tumors more effectively. The trial includes children with progressive glio…

This early-stage trial tests a drug called AZD1390 combined with radiation therapy in people with a fast-growing brain tumor (grade 4 glioma). About 97 participants with either new or returning tumors will receive the drug to see how well it reaches the tumor and if it helps cont…

This early-stage study tests a new drug (BGB-290) combined with chemotherapy (temozolomide) in adolescents and young adults with IDH-mutant gliomas, a type of brain tumor. The goal is to find the safest dose and check for side effects. About 78 participants with newly diagnosed o…

This study tests a new drug called vebreltinib for people with a certain type of recurrent brain cancer (glioblastoma) that has a specific gene change (ZM fusion). About 84 participants will either receive vebreltinib capsules or standard chemotherapy. The main goal is to see if …

This study tested whether a strict, low-calorie ketogenic diet could help people with glioblastoma, an aggressive brain cancer. The diet aims to lower blood sugar and raise ketone levels, which may slow tumor growth. Sixteen adults who had already tried standard treatments took p…

This early-stage study tests whether adding high-dose vitamin C and a special iron drug (ferumoxytol) to standard radiation and chemotherapy can help adults with a newly diagnosed aggressive brain tumor called glioblastoma. The main goal is to find a safe dose of the iron drug. T…

This study tests whether adding an experimental drug called BPM31510 (with vitamin K1) to standard radiation and chemotherapy can help people with newly diagnosed glioblastoma, an aggressive brain cancer. About 50 adults will receive the combination, and researchers will track ho…

This early-stage trial tested a DNA-based vaccine (INO-5401 and INO-9012) combined with an immunotherapy drug (cemiplimab) plus standard radiation and chemotherapy in 52 people with newly diagnosed glioblastoma, an aggressive brain cancer. The goal was to see if the combination i…

This study tests whether giving higher, precisely targeted radiation to the most aggressive parts of a glioblastoma brain tumor can help people live longer. About 30 adults with newly diagnosed glioblastoma will receive this advanced radiation therapy along with the standard chem…

This early-phase study tests whether adding the experimental drug ruxolitinib to standard brain cancer treatment (radiation and temozolomide) is safe and tolerable for people with newly diagnosed aggressive brain tumors called grade III gliomas or glioblastoma. The study involves…

This early-stage study tested whether adding an experimental drug called OKN-007 to standard chemotherapy and radiation is safe for people with newly diagnosed glioblastoma, an aggressive brain cancer. About 27 adults who had surgery for their tumor took part. The main goal was t…

This study tests a new drug called ST101 in people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to find a safe dose and see if the drug can shrink tumors. About 125 adults with cancers like glioblastoma, melanoma, breast, or prostate ca…

This program provides gallium maltolate, an experimental oral drug, to adults with glioblastoma that has come back or not responded to standard treatments. It is for patients who have run out of other options and may still benefit. The goal is to control the disease, not cure it.

This early-stage trial tests a new immune cell therapy for people with recurrent or treatment-resistant malignant glioma, a type of brain cancer. The therapy uses the patient's own T cells, which are modified in the lab to recognize and attack cancer cells. The main goals are to …

This study tests whether removing a margin of healthy-looking brain tissue beyond the visible tumor (supramarginal resection) can extend survival in people with glioblastoma, an aggressive brain cancer. About 90 selected patients will be randomly assigned to standard surgery or t…

This early-phase trial tests a new drug called selinexor alongside standard chemotherapy and radiation for people with newly diagnosed glioblastoma, a fast-growing brain cancer. The main goal is to find the highest safe dose of selinexor that can be given with the standard treatm…

This program offers SurVaxM, an experimental vaccine, to glioblastoma patients who have no other treatment options or who previously benefited from it in a trial. Early data suggest SurVaxM may help extend survival when used alone or with chemotherapy. The goal is to control the …

This study tests whether a high-fat, low-carbohydrate (ketogenic) diet combined with the diabetes drug metformin is safe and tolerable for people with glioblastoma, an aggressive brain cancer. The idea is that lowering blood sugar may slow tumor growth. Participants work with a n…

This study tests whether adding a second chemotherapy drug, lomustine, to the standard treatment (temozolomide plus radiation) helps people with a specific type of glioblastoma (a fast-growing brain cancer). The trial includes 265 newly diagnosed patients whose tumors have a gene…

This early-phase study tests a personalized cell therapy for adults with glioblastoma and children with high-grade gliomas. The treatment uses a patient's own immune cells, modified to target a protein called CD70 on tumor cells and to better navigate to the brain. The main goals…

This early-stage study tests a radioactive drug called [177Lu]Lu-DOTA-TATE in people with glioblastoma, an aggressive brain cancer. For newly diagnosed patients, the drug is given alongside standard radiation and chemotherapy. For those whose cancer has returned, it is given alon…

This study tests whether adding a special radiation tile (GammaTile) during brain surgery for newly diagnosed glioblastoma is safe and practical when combined with standard chemotherapy and radiation. About 61 adults will receive the tile at the time of tumor removal, then contin…

This study tests whether adding the immunotherapy drug nivolumab to radiation and another drug (bevacizumab) can help people with a returning type of aggressive brain cancer called glioblastoma. The trial includes 39 adults whose tumor has a specific genetic marker (MGMT methylat…

This study tests a new drug, azeliragon, combined with radiation therapy for people with a specific type of glioblastoma, an aggressive brain cancer. The goal is to see if this combination is safe and can slow cancer growth. About 30 adults with newly diagnosed, unmethylated glio…

This early-phase trial tests the safety and best dose of mycophenolate mofetil, a drug usually used to prevent organ rejection, when added to standard chemotherapy and radiation for glioblastoma. About 60 adults with newly diagnosed or recurrent glioblastoma will take part. The g…

This study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy and radiation can help people with newly diagnosed glioblastoma, a fast-growing brain cancer. About 52 adults will receive the combination therapy to see if it improves survival and cont…

This trial tests a device implanted in the skull that uses ultrasound to temporarily open the blood-brain barrier, allowing chemotherapy drugs to reach brain tumors more effectively. About 57 adults with recurrent glioblastoma will receive this treatment after surgery to remove t…

This study tests a targeted therapy called abemaciclib in people whose glioblastoma (a type of brain cancer) has come back. The goal is to see if the drug reaches the tumor and helps slow cancer growth. About 45 adults with recurrent glioblastoma will take the drug before surgery…

This study tests an online mind-body program for people with brain tumors (glioma or cancer spread to the brain) and their partners. The program aims to improve spiritual well-being, sleep, mood, and overall quality of life. About 74 couples will take part to see if the program i…

This study aims to understand how immune cells in the blood and bone marrow change over time in people with glioblastoma, a serious brain cancer. Researchers will collect samples from about 40 adults before and during standard treatment. The goal is to gather information that cou…

This study looks at how doctors share information with people who have glioblastoma, a serious brain cancer, and their caregivers. Researchers want to understand how discussions about prognosis and treatment goals happen. The goal is to improve communication so patients and famil…

This study tests a new ultrasound system (SonoClear®) that mimics brain tissue to give surgeons clearer images during brain tumor removal. Fifteen adults with glioma will have their images compared to standard methods. The goal is to see if the system reduces image noise and help…

This study looks at whether advanced MRI scans can better predict how patients with newly diagnosed glioblastoma respond to Optune therapy compared to standard MRI. About 60 participants will be followed to see how many are alive at six months and one year. The goal is to improve…

This study looks back at how 1,000 adults with recurrent malignant gliomas (a type of brain tumor) responded to chemotherapy and targeted therapy. The goal is to learn which treatments work best for different tumor types. No new treatments are given; the study simply collects dat…

This early study looks at how two oral drugs, defactinib and VS-6766, build up in glioblastoma tumors and the surrounding brain tissue. Fourteen adults with new or returning glioblastoma who need surgery will take a single dose of one drug before their operation. The main goals a…

This study explores whether an Apple Watch can detect changes in walking, heart rate, breathing, and sleep in people with glioblastoma (a type of brain cancer). The goal is to see if these measurements can predict symptom changes or complications before they happen. About 25 adul…